Prognostic value of CIP2A gene expression in adult Egyptian acute myeloid leukemia patients

Background Protein phosphatase 2A (PP2A) functions as a tumor suppressor in many cancers. Cancerous inhibitor of protein phosphatase 2A (CIP2A) inhibits PP2A proteolytic degradation of c-Myc and enhances cell growth and tumor formation in several tissues. CIP2A expression in acute myeloid leukemia (...

Full description

Saved in:
Bibliographic Details
Published in:Egyptian Journal of Medical Human Genetics 2020-08, Vol.21 (1), p.31-7
Main Authors: Shafik, Roxan E, Ibrahim, Azza M, Said, Fadwa, Hassan, Naglaa M, Shafik, Hanan E, Shokralla, Hala A
Format: Article
Language:English
Subjects:
Acute myeloid leukemia
AML
c-Myc protein
Cancer
CIP2A
Ethylenediaminetetraacetic acid
Gene expression
Genetic aspects
Leukemia
Medical prognosis
Myc protein
Patients
Phosphatase
Phosphatases
Phosphoprotein phosphatase
Protein phosphatase
Proteolysis
RT-qPCR
Tumor suppressor genes
Tumors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Protein phosphatase 2A (PP2A) functions as a tumor suppressor in many cancers. Cancerous inhibitor of protein phosphatase 2A (CIP2A) inhibits PP2A proteolytic degradation of c-Myc and enhances cell growth and tumor formation in several tissues. CIP2A expression in acute myeloid leukemia (AML) and its effect on outcome of treatment were not reported in Egyptian patients. Results No significant difference was detected in CIP2A expression between AML and control groups (P = 0.48). However, in AML patients, those with low CIP2A expression had a longer median overall survival than those with high expression (P = 0.059). CIP2A expression was not related to the clinical and laboratory variables and did not affect response to treatment. Conclusion High-CIP2A expression was associated with a trend of shorter overall survival in adult Egyptian AML patients. It might serve as a useful marker to predict poor prognosis. CIP2A may represent a potential target for cancer therapy.
ISSN:1110-8630
2090-2441
DOI:10.1186/s43042-020-00075-3